Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including ...

Biogen Inc. closed 49.79% below its 52-week high of $238.00, which the company achieved on July 12th.

Biogen Inc. closed 51.05% below its 52-week high of $238.00, which the company reached on July 12th.

Argus analyst Jasper Hellweg downgraded Biogen (BIIB) to Hold from Buy. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter ...

Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The company’s shares closed last Friday at $115.17.